<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592121</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-101-RCT-001</org_study_id>
    <nct_id>NCT03592121</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of AB-101 in Breast Cancer Survivors</brief_title>
  <official_title>Study to Investigate the Effect of AB-101 in Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Biology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Biology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate the possibility that a topical drug
      could restore nipple sensitivity and improve sexual quality of life in breast cancer
      survivors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately, 80% of breast cancer survivors undergoing will suffer from a permanent reduced
      reduction in nipple sensitivity and associated lowerdecrease in sexual quality of life.
      Currently, there are no treatments for restoring nipple sensitivity and the associatedto
      improve lower sexual quality of life this condition. It would thus be of great clinical
      benefit to post breast surgery patients if a provide a new safe and , effective , topical ,
      on-demand, treatment for this condition can be developed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">October 12, 2019</completion_date>
  <primary_completion_date type="Actual">October 12, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Delayed Orgasm Grade</measure>
    <time_frame>[baseline, week 8]</time_frame>
    <description>Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0
Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax.
This is a binary grading system:
Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Sexual Arousal Disorder</condition>
  <condition>Sexual Dysfunction, Physiological</condition>
  <condition>Breast Cancer</condition>
  <condition>Nipple Disorder</condition>
  <condition>Neuropathy</condition>
  <condition>Cancer of Breast</condition>
  <arm_group>
    <arm_group_label>AB-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-101</intervention_name>
    <description>Apply approximately 1 hour prior to sexual activity</description>
    <arm_group_label>AB-101</arm_group_label>
    <other_name>Phenylephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Apply approximately 1 hour prior to sexual activity</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female breast cancer survivor

          -  Age: 18 to 70

          -  First diagnosed with Stage I or II breast cancer

          -  Have had breast surgery: nipple sparring mastectomy or lumpectomy

          -  At least 3 years post surgery

          -  Nipple neuropathy post breast surgery (change in Llikeart scale &gt;= 3 between pre and
             post surgery)

          -  Baseline nipple sensitivity &lt;=5 (likeartLikert scale)

          -  QoL-BC (&gt;=7)

          -  Delayed orgasm (CTCAE v4.0) Grade 2

          -  One of the following: Delayed orgasm (CTCAE v4.0) Grade 2 and/or Vaginal dryness
             (CTCAE v4.0) Grade 2 or 3

          -  Able to give informed consent

          -  Currently in a monogamous heterosexual relationship for at least 12 months

          -  Sexually active within the last 30 days

          -  Willing to engage in sexual activity at least once a month during the duration of the
             study

          -  Willing to use on a regular basis a web based form system to record sexual events
             i.e., have access to the Internet

          -  Willing to use an adequate method of birth control

          -  Able to comply with the study requirements for 8 consecutive weeks

          -  Able to give informed consent

        Exclusion Criteria:

          -  Previous adverse event to alpha 1 agonists (oral, nasal, topical, or ocular) or drugs
             in this class

          -  Currently pregnant

          -  Nursing within the last 6 months prior to beginning the study

          -  History of cardiovascular or cerebrovascular disease, e.g., heart attack, disease of
             the arteries of the heart, partial heart block, rapid ventricular heartbeat, slow
             heartbeat, chronic heart failure, severe hardening of the arteries, blood clot in an
             artery

          -  Actively being treated for breast cancer

          -  Changes in chronic medication for oncology, cardiology, or endocrinology in past 12
             months

          -  Uncontrolled or severe hypertension

          -  Decreased oxygen in the tissues or blood

          -  Active inflammation of the liver

          -  Acute inflammation of the pancreas

          -  Overactive thyroid gland

          -  Acidosis

          -  Diabetes

          -  Spinal cord injury

          -  Nipple dermatitis

          -  Regional complex pain syndrome

          -  Use of any hypertensive drugs

          -  Use of MAO inhibitors

          -  Subjects assigned to interventional drug arm and failed to report an increase &gt;=2 from
             baseline in nipple sensitivity (likert scale) during phase I

          -  In partners: sexual dysfunction or erectile dysfunction

          -  Currently enrolled in any other medical study or has been enrolled in any medical
             study in the past 30 days

          -  Nipple dermatitis

          -  Regional complex pain syndrome

          -  Unable to provide consent or make allotted clinical visits
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female Breast Cancer Survivors</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Krychman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern CA Center for Sexual Health and Survivorship Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern CA Center for Sexual Health and Survivorship Medicine</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <results_first_submitted>January 8, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nipple Neuropathy, Cancer Survivor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03592121/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AB-101</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
AB-101: Apply approximately 1 hour prior to sexual activity</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Placebo: Apply approximately 1 hour prior to sexual activity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We were unable to recruit a sufficient number of subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>AB-101</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
AB-101: Apply approximately 1 hour prior to sexual activity</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Placebo: Apply approximately 1 hour prior to sexual activity</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delayed Orgasm Grade (CTCAE v4.0)</title>
          <description>CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0
Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax.
This is a binary grading system:
Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship</description>
          <units>Grade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.67" spread="0.58"/>
                    <measurement group_id="B3" value="0.67" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Delayed Orgasm Grade</title>
        <description>Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0
Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax.
This is a binary grading system:
Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship</description>
        <time_frame>[baseline, week 8]</time_frame>
        <population>We were unable to recruit a sufficient number of subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>AB-101</title>
            <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
AB-101: Apply approximately 1 hour prior to sexual activity</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Placebo: Apply approximately 1 hour prior to sexual activity</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Delayed Orgasm Grade</title>
          <description>Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0
Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax.
This is a binary grading system:
Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship</description>
          <population>We were unable to recruit a sufficient number of subjects.</population>
          <units>Grade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>The topical product is used in OTC medications.</desc>
      <group_list>
        <group group_id="E1">
          <title>AB-101</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
AB-101: Apply approximately 1 hour prior to sexual activity</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Placebo: Apply approximately 1 hour prior to sexual activity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andy Goren</name_or_title>
      <organization>Applied Biology, Inc.</organization>
      <phone>(949) 387-4526</phone>
      <email>andyg@appliedbiology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

